Article Text

Download PDFPDF

4CPS-175 Evolution of antimicrobial consumption in a trauma intensive care unit using defined daily doses per 100 occupied bed days
  1. L Gómez-Ganda1,
  2. P Lalueza-Broto1,
  3. ÁG Arévalo-Bernabé1,
  4. A Rey-Pérez2,
  5. J Baena-Caparrós2,
  6. L Domenech-Moral1,
  7. M Baguena-Martínez2
  1. 1Vall D’hebron University Hospital, Pharmacy Service, Barcelona, Spain
  2. 2Vall D’hebron University Hospital, Trauma Intensive Care Service, Barcelona, Spain


Background and importance Microbial resistance to antimicrobial treatment constitutes a public health problem, principally in the hospital environment.

Aim and objectives To evaluate the evolution of antimicrobial consumption in a trauma intensive care unit (ICUt) using defined daily doses per 100 occupied bed days (DDD/100 OBD).

Material and methods A retrospective study was conducted at a third level hospital including all patients admitted to the ICUt from January 2016 to December 2018. We collected biodemographic and clinical data of patients, and annual DDD/100 OBD and DDD/100 OBD for each antimicrobial drug. We used DDD established by the WHO’s International Working Group for Drug Statistics Methodology of Norway.

Results A total of 1206 patients (68.0% men) were included with a median age of 54±19 years. The main diagnosis was trauma (74.3%). Biodemographic and clinical data were similar for the 3 years.

In 2016, DDD/100 OBD were 131.12: DDD/100 OBD for penicillins were 60.00 (amoxicillin/clavulanate 33.90, piperacillin/tazobactam 12.39), cephalosporins 13.95, fluoroquinolones 3.70, carbapenems 1532 (meropenem 14.34), aminoglycosides 3.15, daptomycin 3.36, linezolid 2.38, glycopeptides 4.11 and antifungals 7.34 (fluconazole 6,48).

In 2017, DDD/100 OBD were 137.62: DDD/100 OBD for penicillins were 54.77 (amoxicillin/clavulanate 35.03, piperacillin/tazobactam 8.37), cephalosporins 16.14, fluoroquinolones 9.42, carbapenems 16.00 (meropenem 15.36), aminoglycosides 2.86, daptomycin 4.68, linezolid 3.27, glycopeptides 3.05 and antifungals 3.69 (fluconazole 2.76).

In 2018, DDD/100 OBD were 133.09: DDD/100 OBD for penicillins were 60.42 (amoxicillin/clavulanate 39.81, piperacillin/tazobactam 6.76), cephalosporins 14.37, fluoroquinolones 7.07, carbapenems 15.03 (meropenem 13.08), aminoglycosides 5.69, daptomycin 2.35, linezolid 3.32, glycopeptides 3.85 and antifungals 3.74 (fluconazole 3.35).

From 2016 to 2018, the results showed:

  • Important reduction in DDD/100 OBD for piperacillin/tazobactam (−45.46%) but an increase in DDD/100 OBD for amoxicillin/clavulanate (+17.42%).

  • Stable use of cephalosporins, with a minimum consumption of ceftolozane/tazobactam (<1.5%).

  • Stable consumption of carbapenems, with meropenem being the most prescribed (>87%) and reduction in the use of imipenem/cilastatin (−32.51%).

  • Reduction in prescription of antifungals (−49.02%), with fluconazole the most used (>74%).

Conclusion and relevance Reduction of piperacillin/tazobactam use with an increase in amoxicillin/clavulanate prescriptions showed a decrease in extended spectrum penicillin consumption and could demonstrate the appropriateness of empirical therapy. Low ceftolozane/tazobactam prescriptions demonstrated controlled prescription of restricted use cephalosporins. Minimum imipenem/cilastatin use could be in relation to its neurotoxic effects. The results indicate an adequate use of antifungals.

References and/or acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.